Clinical Trials Logo

Breast Neoplasms clinical trials

View clinical trials related to Breast Neoplasms.

Filter by:

NCT ID: NCT01072838 Terminated - Breast Cancer Clinical Trials

Safety Study for Short-course Accelerated, Hypofractionated Partial Breast Radiotherapy (APBI) in Women With Early Stage Breast Cancer Using the Contura MLB

Start date: December 2009
Phase: Phase 2
Study type: Interventional

To determine local disease control (recurrence) with shorter course of APBI delivered with a breast brachytherapy applicator.

NCT ID: NCT01072318 Enrolling by invitation - Breast Cancer Clinical Trials

Extended Adjuvant Treatment With Letrozole in Breast Cancer Who Complete 5 Years of Toremifene

LEXTOP
Start date: January 2010
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess Efficacy and Safety of Extended Adjuvant Treatment With Letrozole in Postmenopausal Women With Hormone Receptor Positive Breast Cancer Who Complete 5 Years of Toremifene

NCT ID: NCT01071564 Terminated - Clinical trials for Stage IV Breast Cancer

RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery

Start date: November 2009
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of RO4929097 (gamma-secretase/Notch signalling pathway inhibitor RO4929097) when given together with vismodegib in treating patients with breast cancer that is metastatic or cannot be removed by surgery. RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as vismodegib, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving RO4929097 and vismodegib together may slow the growth of tumor cells and may be a more active treatment for advanced breast cancer.

NCT ID: NCT01071109 Not yet recruiting - Breast Cancer Clinical Trials

The Clinical and Biochemical Effect of Therapeutic Massage on Fatigue and Insomnia in Women With Breast Cancer Receiving Radiation Therapy

RTTM301
Start date: November 2010
Phase: N/A
Study type: Interventional

A majority of women with breast cancer receive radiation therapy, and many of them experience the debilitating side effects of fatigue and insomnia. There is a need for an effective treatment that could ameliorate these symptoms and improve quality of life in the radiation therapy population. The primary purpose of the proposed research is to study the impact of massage therapy as a tool for the management of fatigue and insomnia experienced by women diagnosed with breast cancer and receiving radiation therapy. The secondary purpose is to explain, at the biochemical level, the effect of therapeutic massage on the level of fatigue and insomnia in radiation therapy patients. Prior studies have shown an association between fatigue and insomnia in the breast cancer patient following radiation therapy and the presence of inflammation as evidenced by increased proinflammatory cytokine production. The investigators hypothesize that therapeutic massage will ameliorate the symptoms of fatigue and insomnia associated with radiation therapy, and will be associated with a reduction in the plasma levels of interleukin-6 (IL-6),soluble IL-6 receptor (sIL-6R/CD126), and C-Reactive Protein (CRP). This reduction in proinflammatory biomarkers will be due to the activation of the cholinergic anti-inflammatory pathway via the activation of the vagus nerve.

NCT ID: NCT01070706 Completed - Breast Cancer Clinical Trials

Phase Ib/II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and Sunitinib

PGS
Start date: March 2009
Phase: Phase 1/Phase 2
Study type: Interventional

Phase Ib part: ▪ Primary objective: To demonstrate the recommended dose of the combination of paclitaxel, gemcitabine, and sunitinib (sutene®) (PGS) as preoperative chemotherapy in patients with HER2-negative operable breast cancer - Secondary objective: 1. To demonstrate the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of this regimen 2. To determine the safety profile Phase II part - Primary objective: To evaluate the pathologic complete response rate (pCR) to preoperative administration of PGS ▪ Secondary objective: 1. To assess breast conserving rate after preoperative PGS 2. To evaluate clinical response rate, disease free survival (DFS), and overall survival (OS) 3. To assess the safety profiles of PGS

NCT ID: NCT01070485 Completed - Breast Cancer Clinical Trials

BAY88-8223, Alpharadin, Breast Cancer Patients With Bone Dominant Disease

Start date: January 2010
Phase: Phase 2
Study type: Interventional

The purpose of the study is to investigate if multiple (up to four) intravenous injections of Xofigo (Alpharadin) have any clinically relevant effect on bone markers in breast cancer patients with bone dominant disease who have progressed on endocrine therapy and are no longer considered suitable for endocrine therapy. In addition the safety of Xofigo (Alpharadin) will be assessed.

NCT ID: NCT01069796 Terminated - Clinical trials for Triple Negative Metastatic Breast Cancer

Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer

Start date: April 2010
Phase: Phase 2
Study type: Interventional

Patients with triple negative metastatic breast cancer (HER2-, PR-, ER-) will receive bevacizumab, paclitaxel and capecitabine as a first line of treatment (possibility to have received adjuvant chemotherapy).

NCT ID: NCT01069211 Recruiting - Breast Cancer Clinical Trials

Clinical Outcomes After Letrozole Treatment According to the Estrogen Receptor Expression in Postmenopausal Women

LETTER
Start date: January 2010
Phase: Phase 4
Study type: Observational

The purpose of this study is to assess clinical outcomes after Letrozole treatment according to the estrogen receptor expression in postmenopausal women with hormone receptor positive breast cancer.

NCT ID: NCT01069081 Completed - Breast Cancer Clinical Trials

Docetaxel and Cisplatin Chemotherapy With or Without High Dose Proton Pump Inhibitor in Metastatic Breast Cancer

Start date: August 2009
Phase: Phase 2
Study type: Interventional

The objectives of this study are to evaluate the efficacy and tolerability of high dose proton pump inhibitor combined with chemotherapy in metastatic breast cancer.

NCT ID: NCT01068704 Completed - Breast Cancer Clinical Trials

Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer

Start date: June 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if BMS-690514 + letrozole will be more effective than lapatinib + letrozole in patients who have metastatic hormone receptor positive breast cancer after developing progressive disease immediately following adjuvant antiendocrine therapy